Cosciens Biopharma Stock Beta
| CSCI Stock | 3.13 0.04 1.29% |
COSCIENS Biopharma fundamentals help investors to digest information that contributes to COSCIENS Biopharma's financial success or failures. It also enables traders to predict the movement of COSCIENS Stock. The fundamental analysis module provides a way to measure COSCIENS Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to COSCIENS Biopharma stock.
COSCIENS | Beta |
COSCIENS Biopharma Company Beta Analysis
COSCIENS Biopharma's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current COSCIENS Biopharma Beta | 2.27 |
Most of COSCIENS Biopharma's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, COSCIENS Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
COSCIENS Beta Driver Correlations
Understanding the fundamental principles of building solid financial models for COSCIENS Biopharma is extremely important. It helps to project a fair market value of COSCIENS Stock properly, considering its historical fundamentals such as Beta. Since COSCIENS Biopharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of COSCIENS Biopharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of COSCIENS Biopharma's interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, COSCIENS Biopharma has a Beta of 2.274. This is 164.42% higher than that of the Biotechnology sector and 63.6% higher than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
COSCIENS Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses COSCIENS Biopharma's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of COSCIENS Biopharma could also be used in its relative valuation, which is a method of valuing COSCIENS Biopharma by comparing valuation metrics of similar companies.COSCIENS Biopharma is currently under evaluation in beta category among its peers.
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, COSCIENS Biopharma will likely underperform.
COSCIENS Fundamentals
| Return On Equity | -0.66 | ||||
| Return On Asset | -0.23 | ||||
| Operating Margin | (1.61) % | ||||
| Current Valuation | (13.04 M) | ||||
| Shares Outstanding | 3.12 M | ||||
| Shares Owned By Insiders | 1.32 % | ||||
| Shares Owned By Institutions | 6.69 % | ||||
| Number Of Shares Shorted | 1.34 K | ||||
| Price To Book | 0.49 X | ||||
| Price To Sales | 2.66 X | ||||
| Revenue | 7.26 M | ||||
| EBITDA | (17.99 M) | ||||
| Net Income | (3.55 M) | ||||
| Total Debt | 3.59 M | ||||
| Book Value Per Share | 8.57 X | ||||
| Cash Flow From Operations | (2.73 M) | ||||
| Short Ratio | 1.64 X | ||||
| Earnings Per Share | (2.69) X | ||||
| Beta | 2.27 | ||||
| Market Capitalization | 13.08 M | ||||
| Total Asset | 31.45 M | ||||
| Retained Earnings | 6.17 M | ||||
| Working Capital | 13.11 M | ||||
| Net Asset | 31.45 M |
About COSCIENS Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze COSCIENS Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of COSCIENS Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of COSCIENS Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether COSCIENS Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of COSCIENS Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cosciens Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cosciens Biopharma Stock:Check out COSCIENS Biopharma Piotroski F Score and COSCIENS Biopharma Altman Z Score analysis. For more detail on how to invest in COSCIENS Stock please use our How to Invest in COSCIENS Biopharma guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of COSCIENS Biopharma. If investors know COSCIENS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about COSCIENS Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.69) | Revenue Per Share 3.759 | Quarterly Revenue Growth 0.041 | Return On Assets (0.23) | Return On Equity (0.66) |
The market value of COSCIENS Biopharma is measured differently than its book value, which is the value of COSCIENS that is recorded on the company's balance sheet. Investors also form their own opinion of COSCIENS Biopharma's value that differs from its market value or its book value, called intrinsic value, which is COSCIENS Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because COSCIENS Biopharma's market value can be influenced by many factors that don't directly affect COSCIENS Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between COSCIENS Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if COSCIENS Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, COSCIENS Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.